Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients

被引:356
作者
Regidor, Deborah L.
Kopple, Joel D.
Kovesdy, Csaba P.
Kilpatrick, Ryan D.
McAllister, Charles J.
Aronovitz, Jason
Greenland, Sander
Kalantar-Zadeh, Kamyar
机构
[1] Harbor UCLA Med Ctr, Div Nephrol & Hypertens, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[2] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA
[4] Dept Vet Affairs, Salem, VA USA
[5] DaVita Inc, El Segundo, CA USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 04期
关键词
D O I
10.1681/ASN.2005090997
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Although treating anemia of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve survival, most studies have examined associations between baseline hemoglobin values and survival and ignored variations in clinical and laboratory. measures over time. It is not clear whether longitudinal changes in hemoglobin or administered ESA have meaningful associations with survival after adjustment for time-varying confounders. With the use of time-dependent Cox regression models, longitudinal associations were examined between survival and quarterly (13-wk averaged) hemoglobin values and administered ESA dose in a 2-yr (July 2001 to June 2003) cohort of 58,058 maintenance hemodialysis patients from a large dialysis organization (DaVita) in the United States. After time-dependent and multivariate adjustment for case mix, quarterly varying administered intravenous iron and ESA doses, iron markers, and nutritional status, hemoglobin levels between 12 and 13 g/dl were associated with the greatest survival. Among prevalent patients, the lower range of the recommended Kidney Disease Quality Outcomes Initiative hemoglobin target (11 to 11.5 g/dl) was associated with a higher death risk compared with the 11.5- to 12-g/dl range. A decrease or increase in hemoglobin over time was associated with higher or lower death risk, respectively, independent of baseline hemoglobin. Administration of any dose of ESA was associated with better survival, whereas among those who received ESA, requiring higher doses were surrogates of higher death risk. In this observational study, greater survival was associated with a baseline hemoglobin between 12 and 13 g/dl, treatment with ESA, and rising hemoglobin. Falling hemoglobin and requiring higher ESA doses were associated with decreased survival. Randomized clinical trials are required to examine these associations.
引用
收藏
页码:1181 / 1191
页数:11
相关论文
共 48 条
[21]   Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction [J].
Kalantar-Zadeh, K ;
Kilpatrick, RD ;
Kuwae, N ;
McAllister, CJ ;
Alcorn, H ;
Kopple, JD ;
Greenland, S .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (09) :1880-1888
[22]   Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients [J].
Kalantar-Zadeh, K ;
McAllister, CJ ;
Lehn, RS ;
Lee, GH ;
Nissenson, AR ;
Kopple, JD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (04) :761-773
[23]   Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population - The 58th Annual Fall Conference and Scientific Sessions [J].
Kalantar-Zadeh, K ;
Kilpatrick, RD ;
McAllister, CJ ;
Greenland, S ;
Kopple, JD .
HYPERTENSION, 2005, 45 (04) :811-817
[24]   Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease? [J].
Kausz, AT ;
Solid, C ;
Pereira, BJG ;
Collins, AJ ;
Peter, WS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (01) :136-147
[25]  
LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573
[26]   Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings [J].
Locatelli, F ;
Pisoni, RL ;
Akizawa, T ;
Cruz, JM ;
DeOreo, PB ;
Lameire, NH ;
Held, PJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (05) :S27-S33
[27]   Application of dialysis and transplant registries to clinical practice: the Lombardy Registry [J].
Locatelli, F ;
Tentori, F ;
Del Vecchio, L ;
Pontoriero, G .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 :2-4
[28]   The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry [J].
Locatelli, F ;
Conte, F ;
Marcelli, D .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (07) :1642-1644
[29]  
Longenecker JC, 2000, J AM SOC NEPHROL, V11, P520, DOI 10.1681/ASN.V113520
[30]   Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state, and erythropoietin resistance [J].
López-Gómez, JM ;
Pérez-Flores, I ;
Jofré, R ;
Carretero, D ;
Rodríguez-Benitez, P ;
Villaverde, M ;
Pérez-García, R ;
Nassar, GM ;
Niembro, E ;
Ayus, JC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (09) :2494-2501